ClinicalTrials.gg

Program

ABBV-547

A development code.

In AbbVie's pipeline, IL-23. Its studies are mostly in Arthritis, Psoriatic · Psoriasis, led by AbbVie.

Furthest: phase 2, since Mar 4, 20252 company-led studies, 2 open or runningNext primary completion: May 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie22 open or runningphase 2since Mar 4, 2025Mar 4, 2025May 2028phase 1 · NCT07232004
  • Named in AbbVie’s own pipeline as ABBV-547, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2025First study: phase 2 study in Arthritis, PsoriaticFirst studyNCT06865105 · 300 planned · United States, Canada, Czechia and more
  2. Nov 14, 2025Phase 1 study in PsoriasisNCT07232004 · 142 enrolled · United States, Japan
  3. Oct 15, 2026Primary completion moved from 2027-08 to 2028-05Date moved laterphase 1 · +9 months · NCT07232004
  4. Nov 9, 2026Primary completion moved from 2027-12 to 2029-08Date moved laterphase 2 · +20 months · NCT06865105

Ahead

  1. May 2028Primary completion: phase 1 study in PsoriasisNCT07232004
  2. Aug 2029Primary completion: phase 2 study in Arthritis, PsoriaticNCT06865105

TargetBeta

“IL-23”the company's pipeline, read by Claude · source

Other programs on IL23A

ProgramCompanyFurthest phaseStudies
risankizumabruleAbbViephase 468
guselkumabruleJohnson & Johnsonphase 460
mirikizumabruleEli Lillyphase 436
SHR-1139Jiangsu HengRui Medicinephase 28
GSK4528287GlaxoSmithKlinephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07232004Psoriasis · United States, Japan1Active, not recruitingMay 2028142
NCT06865105Arthritis, Psoriatic · United States, Canada, Czechia and more2RecruitingAug 2029300

How it is read

Names in the registry

  • “ABBV-547”, 2 entries

Codes read as this program: ABBV547.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.